Cybin Inc. (OTCMKTS:CYBN – Get Free Report) shares traded up 1.8% during mid-day trading on Thursday . The stock traded as high as $10.40 and last traded at $10.19. 266,856 shares traded hands during trading, an increase of 32% from the average session volume of 201,422 shares. The stock had previously closed at $10.01.
Cybin Stock Up 1.8 %
The company’s fifty day moving average is $9.85 and its two-hundred day moving average is $6.39. The stock has a market cap of $203.72 million, a price-to-earnings ratio of -53.63 and a beta of 0.44.
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Stories
- Five stocks we like better than Cybin
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Using the MarketBeat Dividend Tax Calculator
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
